Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $9.3B; returns 1 day -0.1%, 1 week +5.7%, 1 year +91.8%.

Kymera Therapeutics Inc. (NASDAQ: KYMR) is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases. Their approach involves targeted protein degradation (TPD) to create novel medicines. Kymera is working on treatments for diseases that have been difficult to treat with traditional methods.

Groups KYMR belongs to

• Biotechnology
• Clinical Stage Biotech
• Healthcare
• Life Sciences
• Biopharmaceutical
• Clinical Stage
• Pharmaceuticals
• Autoimmune Diseases
• Fast Track Designation

KYMR financial model: income statement, cash flow and balance sheet